Tumor-specific antibody-mediated targeted delivery of Doxil® reduces the manifestation of auricular erythema side effect in mice
- 2 February 2008
- journal article
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 357 (1-2) , 272-279
- https://doi.org/10.1016/j.ijpharm.2008.01.041
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell linesEuropean Journal of Pharmaceutical Sciences, 2007
- Antinucleosome Antibody-Modified Liposomes and Lipid-Core Micelles for Tumor-Targeted Delivery of Therapeutic and Diagnostic AgentsJournal of Liposome Research, 2007
- Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studiesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2006
- Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysisAnti-Cancer Drugs, 2006
- Sequential Combination of Paclitaxel-Carboplatin and Paclitaxel-Liposomal Doxorubicin as a First-Line Treatment in Patients with Ovarian CancerOncology, 2005
- The Costs and Efficacy of Liposomal Doxorubicin in Platinum-Refractory Ovarian Cancer in Heavily Pretreated PatientsGynecologic Oncology, 2001
- p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groupsBiochimica et Biophysica Acta (BBA) - Biomembranes, 2001
- Skin Toxic Effects of Polyethylene Glycol–Coated Liposomal DoxorubicinArchives of Dermatology, 2000
- Phase II Study of Liposomal Doxorubicin in Platinum- and Paclitaxel-Refractory Epithelial Ovarian CancerJournal of Clinical Oncology, 2000
- Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2Annals of Oncology, 2000